Thursday, Aurobindo Pharma announced that its wholly-owned subsidiary, CuraTeQ Biologics, planned to invest around Rs 300 crore in expanding the capacity of its biologics manufacturing facilities.
Aurobindo Pharma disclosed in a regulatory filing that the board of directors of CuraTeQ Biologics Pvt Ltd approved the expansion of its operations by creating another mammalian cell culture manufacturing facility with a higher capacity to fulfil future demands.
“The estimated capital cost for capacity expansion is around Rs 300 crore,” the report stated, adding that the facility is expected to be fully operational by FY26.
In addition, the board authorised contract manufacturing operations (CMO) for biologicals to maximise capacity utilisation.
CuraTeQ will actively seek customers in the CMO domain, since the global demand for contract manufacturing of biologics is expanding at a rate of 8 to 10 percent, according to the statement.
The firm also said that the board of directors of its second wholly-owned subsidiary, Auro Vaccines Pvt Ltd, has approved studying the possibility of offering contract manufacturing services to global vaccine makers in order to maximise the use of its existing manufacturing capacity.
Auro Vaccines is in the business of developing and producing biological vaccines.